$94.98 +0.71 (%) Medivation Inc - NASDAQ

Oct. 20, 2014 | 04:00 PM

Partner Headlines

  1. J&J Earnings Beat; Olysio Chatter Hits Gilead

    IBD | Oct. 14, 2014 | 11:54AM EST
  2. Consider Medivation for Your Portfolio

    FoxBusiness | Oct. 6, 2014 | 13:31PM EST
  3. Benzinga's Top Downgrades

    Benzinga | Sep. 24, 2014 | 08:52AM EST
  4. Goldman Sachs Downgrades Medivation To Neutral, Shares Drop

    Benzinga | Sep. 24, 2014 | 08:38AM EST
  5. These 3 Biotech Stocks Just Hit New Highs

    Benzinga | Sep. 22, 2014 | 13:31PM EST
  6. Fast Money Halftime Report Final Trade From September 12

    Benzinga | Sep. 12, 2014 | 22:04PM EST
  7. Medivation Eyes Blockbuster As Cancer Drug Gets An OK

    IBD | Sep. 11, 2014 | 17:41PM EST
  8. Stifel Raises Medivation Inc Price Target

    Benzinga | Sep. 11, 2014 | 08:32AM EST
  9. Stocks Hitting 52-Week Highs

    Benzinga | Sep. 10, 2014 | 10:05AM EST
  10. A Few Reasons Why Investors Should Consider Dendreon for Their Portfolio

    GuruFocus | Aug. 15, 2014 | 12:18PM EST
  11. Medivation Cancer Drug Fuels Beat, Swings To Profit

    IBD | Aug. 8, 2014 | 11:55AM EST
  12. Benzinga's Volume Movers

    Benzinga | Aug. 8, 2014 | 10:32AM EST
  13. Medivation Announces Change in Executive Management Team; Dawn Svoronos To Chief Commercial Officer

    Benzinga | Jul. 10, 2014 | 16:11PM EST
  14. Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector

    Benzinga | Jul. 3, 2014 | 12:26PM EST
  15. Aegis Capital Believes Seragon Deal Underscores Value In Medivation

    Benzinga | Jul. 2, 2014 | 10:28AM EST
  16. UPDATE: Stifel Reiterates On Medivation Following Prostate Cancer Survey

    Benzinga | Jun. 23, 2014 | 09:33AM EST
  17. Benzinga's Top Upgrades

    Benzinga | Jun. 19, 2014 | 07:46AM EST
  18. US Stock Futures Flat Ahead Of International Trade Data

    Benzinga | May. 6, 2014 | 07:29AM EST
  19. UPDATE: Canaccord Genuity Initiates Coverage on Medivation as Urologist Uptake is Unclear

    Benzinga | Apr. 16, 2014 | 09:45AM EST
  20. Morning Market Movers

    Benzinga | Apr. 1, 2014 | 09:43AM EST
  21. Stocks To Watch For April 1, 2014

    Benzinga | Apr. 1, 2014 | 04:22AM EST
  22. Celegene, Pharmacyclics Lead Biotech Short Interest Trend (CELG, MDVN, PCYC)

    Benzinga | Mar. 26, 2014 | 07:56AM EST
  23. UPDATE: Astellas Announces Marketing Approval in Japan for XTANDI® (enzalutamide) Capsules, an Advanced Prostate Cancer Treatment

    Benzinga | Mar. 24, 2014 | 16:11PM EST
  24. BioMarin, Medivation Buck Biotech Short Interest Trend (BIIB, BMRN, MDVN)

    Benzinga | Mar. 12, 2014 | 10:01AM EST
  25. Market Wrap For February 28: Markets Unable To Hold On To Gains

    Benzinga | Feb. 28, 2014 | 16:53PM EST
  26. Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE Moving Higher, ELGX, DECK, MDVN, CGEN, ARNA Lowr

    Benzinga | Feb. 28, 2014 | 10:40AM EST
  27. Benzinga's Top #PreMarket Losers

    Benzinga | Feb. 28, 2014 | 08:15AM EST
  28. 2 Deaths, 25% Plunge -- And Still A Big Upside

    YCharts | Feb. 12, 2014 | 09:31AM EST
  29. Mid-Afternoon Market Update: Fed Will Continue the Taper in February

    Benzinga | Jan. 29, 2014 | 15:31PM EST
  30. Mid-Day Market Update: Yahoo! Slips After Q4 Results; RF Micro Shares Rise

    Benzinga | Jan. 29, 2014 | 12:35PM EST
  31. New Year Short Interest Swings In Biotech (BIIB, BMRN, MDVN)

    Benzinga | Jan. 29, 2014 | 11:44AM EST
  32. Mid-Morning Market Update: Markets Open Lower; Dow Chemical Posts Upbeat Profit

    Benzinga | Jan. 29, 2014 | 10:22AM EST
  33. Stocks Hitting 52-Week Highs

    Benzinga | Jan. 29, 2014 | 10:07AM EST
  34. Benzinga's Top #PreMarket Gainers

    Benzinga | Jan. 29, 2014 | 08:09AM EST
  35. Medivation and Astellas Announce Final Results From the Phase 3 PREVAIL Trial of Enzalutamide

    Benzinga | Jan. 28, 2014 | 17:03PM EST
  36. UPDATE: Aegis Capital Reiterates on Medivation Following In-Line 3Q 2013 Financial Results

    Benzinga | Nov. 13, 2013 | 10:54AM EST
  37. Medivation, Astellas Announce Phase 3 PREVAIL Trial of Enzalutamide Met Co-Primary Endpoints

    Benzinga | Oct. 22, 2013 | 07:46AM EST
  38. Uh Oh: Is This Cancer Highflyer In Your Account?

    YCharts | Sep. 19, 2013 | 09:27AM EST
  39. Worse-Than-Expected Xtandi Sales Hitting Shares of Medivation; William Blair Comments on Miss

    Benzinga | Aug. 1, 2013 | 12:02PM EST
  40. Medivation Elects Kathryn Falberg to Board of Directors

    Benzinga | Feb. 4, 2013 | 09:11AM EST
  41. Medivation Bulls Load Up on Call Options

    SchaeffersResearch | Dec. 27, 2012 | 10:33AM EST
  42. Aegis Capital Corp. Reiterates Buy Rating, $100 PT on Medivation

    Benzinga | Dec. 26, 2012 | 03:40AM EST
  43. Medivation, Inc. (MDVN) President and CEO David Hung sells 10,246 Shares

    GuruFocus | Dec. 11, 2012 | 13:12PM EST
  44. Benzinga's Top Initiations

    Benzinga | Dec. 4, 2012 | 00:40AM EST
  45. Celgene, Regeneron Pharmaceutical Lead Biomed Group

    IBD | Nov. 30, 2012 | 10:21AM EST
  46. Medivation Inc. (MDVN) Chief Business Officer and CFO Clarence Patrick Machado sells 20,000 Shares

    GuruFocus | Oct. 3, 2012 | 17:00PM EST
  47. UPDATE: Citigroup Reiterates Buy Rating, Raises PT on Medivation

    Benzinga | Oct. 3, 2012 | 05:32AM EST
  48. Medivation Effects 2-for-1 Stock Split

    Benzinga | Sep. 24, 2012 | 01:14AM EST
  49. Three Biotech Stocks Analysts Are Keen On (MDVN, GEVA, OPTR)

    Benzinga | Sep. 5, 2012 | 09:34AM EST
  50. US FDA Approves XTANDI for Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

    Benzinga | Aug. 31, 2012 | 08:23AM EST
Trading Center